Search clinical trials for: sintilimab maintenance

Total 935 results

Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NPC

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Peking University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Phase I Study of Sintilimab in Healthy Chinese Male Subjects

Healthy Male Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H

China
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Completed

Heart-Healthy Lenoir Lifestyle Study

Obesity | Cardiovascular Disease

United States
The Miriam Hospital

Completed

Weight Maintenance Study for 2007 Shape UP RI Participants (STOPRegain)

Weight Loss

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Sun Yat-sen University

Not yet recruiting

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Non Clear Cell Renal Carcinoma

China
West China Hospital
First Affiliated Hospital of Chongqing Medical University; Sichuan Cancer Hospital... and other collaborators

Recruiting

Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer

Rectal Cancer | Radiotherapy | Anti-PD-1 Antibody | MSI-H | Mmr Deficiency

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Second Affiliated Hospital of Guangzhou Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaborators

Active, not recruiting

Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC (REGSIN)

Hepatocellular Carcinoma Non-resectable

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid Tumor

Advanced or Metastatic Solid Tumors

China
RenJi Hospital

Not yet recruiting

Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab

Third-line Treatment | Dvanced Duodenal Adenocarcinoma | Furquinelone Combined With Sintilimab
Beijing Tsinghua Chang Gung Hospital

Unknown

Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma | Portal Vein Tumor Thrombosis

China
Changzhou Cancer Hospital of Soochow University

Unknown

Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung Cancer

Small Cell Lung Cancer

China
Xiaorong Dong

Unknown

SRS Sequential Sindilimab in Brain Metastasis of NSLSC

Brain Metastases | NSCLC Stage IV | Sintilimab | SRS

China
University of Connecticut
National Institute of Nursing Research (NINR); University of Southern California and other collaborators

Completed

Physical Activity Choices Everyday (PACE)

Obesity

United States
Norwegian University of Science and Technology
St. Olavs Hospital

Completed

Impact of Ketogenic Diets in Preventing Relapse in Obesity Management (Ketomaintain)

Obesity

Norway
Pfizer

Completed

PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-2b/3)

Alopecia Areata

China, United States, Spain, Korea, Republic of, Taiwan, Canada, Australia, Germany, Czechia, Poland, Hungary, Japan, United Kingdom, Argentina, Chile, Colombia, Mexico, Russian Federation
VA Office of Research and Development

Completed

Development of a Weight Maintenance Intervention for Bariatric Surgery Patients (MAINTAIN-B)

Obesity, Morbid

United States
Lundquist Institute for Biomedical Innovation at...

Unknown

Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need

Overactive Bladder

United States
Schön Klinik Berchtesgadener Land
Bavarian State Ministry of Health and Care (Funding); Betriebskrankenkassen... and other collaborators

Recruiting

Effects of Rehabilitation Combined With a Maintenance Program Compared to Rehabilitation Alone in Post-COVID-19 (ReLoAd2)

Post-COVID-19 Syndrome

Germany
Slagelse Hospital
University of Southern Denmark; Holbaek Sygehus; University College Copenhagen; City of Slagelse (municipality)

Recruiting

Maintenance of Physical Activity After Cardiac Rehabilitation (FAIR)

Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Heart Failure | Heart Arrest | Arrythmia

Denmark
Peking Union Medical College Hospital
Henan Cancer Hospital; Qilu Hospital of Shandong University; Beijing Tongren... and other collaborators

Recruiting

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Shanghai Changzheng Hospital

Completed

Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)

Colorectal Cancer | Immunotherapy | Sintilimab | First-line Treatment | Anlotinib | Chemo-free Therapy

China
AIPING ZHOU

Unknown

Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients

Colorectal Cancer

China
Tongji Hospital

Not yet recruiting

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Hepatic Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy

Pancreatic Carcinoma | Neuroendocrine Carcinoma | Neuroendocrine Tumor Grade 3

China
The First Affiliated Hospital of Xiamen University

Not yet recruiting

Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer

Multiple Primary Lung Cancer
Sun Yat-sen University

Completed

Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma

Radiotherapy | Sintilimab | Anlotinib | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Early Stage | Peg-aspargase | Phase Two | Open

China
Pennington Biomedical Research Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Oregon... and other collaborators

Recruiting

A Weight Maintenance Program Promoting Fat Loss in Pregnancy in Women With Obesity (Healthy Mamas)

Obesity | Gestational Weight Gain

United States
Sun Yat-sen University

Unknown

Maintenance Treatment With S-1 in Gastric Cancer Patients

Gastric Cancer Stage IV | Cancer of Stomach

China
University of California, San Francisco
Mental Insight Foundation

Active, not recruiting

Optimizing Mindfulness Based Cognitive Therapy (MBCT) Maintenance (OMM)

Depression

United States
University of Manitoba

Completed

Long Term Comparison of Ultrasonic and Hand Instrumentation in the Maintenance of Peri-implant Tissues: A Randomized Clinical Trial

Determination of Clinical Effects | Presence of Inflammatory Cytokines | Patients Perception of Discomfort | Titanium Scalers | Ultrasonics

Canada
University of Pittsburgh
Department of Health and Human Services

Recruiting

Wheelchair Maintenance Training Program

Remote Maintenance Training Program

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
Zhejiang Cancer Hospital

Not yet recruiting

Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial

Metastatic Breast Cancer

China
Tianjin Medical University Second Hospital

Not yet recruiting

Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung Cancer

Lung Neoplasms | Oligometastasis
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
University of Hawaii
Queen's Medical Center; I Ola Lahui, Inc.; Ke Ola Mamo; Queen Lili'uokalani Children... and other collaborators

Completed

PILI at Work a 5-Year Controlled Intervention Trial: Testing DVD Versus Group Delivery of a Weight-Loss Maintenance Intervention in Native Hawaiian- Serving Worksites (P@W)

Obesity | Overweight | Weight Loss | Weight Loss Maintenance

United States
Fujian Haixi Pharmaceuticals Co., Ltd.

Recruiting

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Solid Tumor

China
Xin-Hua Xu

Recruiting

The Clinical Significance of Peripheral Blood T Lymphocyte PD-1 Expression and T Cell Subset Distribution.

Hepatocellular Carcinoma

China
Wuhan Union Hospital, China

Not yet recruiting

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Unresectable Advanced Solid Tumors | Biliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer

China
Peking University

Recruiting

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Neuroendocrine Neoplasm

China
Fujian Medical University Union Hospital

Not yet recruiting

Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection

Esophageal Squamous Cell Carcinoma Thoracic Stage II | Esophageal Squamous Cell Carcinoma Thoracic Stage III | Esophageal Squamous Cell Carcinoma Thoracic Stage IV

China
Taizhou Hospital

Recruiting

Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer (CRTCP)

Cervical Cancer

China

Search clinical trials for: sintilimab maintenance

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations